NK Cells Can Preferentially Target Prostate Cancer Stem-like Cells via the TRAIL/DR5 Signaling Pathway

Taiga Seki1, Yui Shimizu2, Kyota Ishii1

  • 1Graduate School of Food and Nutritional Sciences, Toyo University, Gunma 347-0193, Japan.

Biomolecules
|November 27, 2021
PubMed
Abstract

Insights

Natural killer (NK) cells show enhanced cytotoxicity against prostate cancer stem cells. This targeted elimination via the TRAIL/DR5 pathway offers a potential strategy for treating androgen-dependent prostate cancer.

Area of Science:

  • Immunology
  • Oncology
  • Cell Biology

Background:

  • Androgen-dependent prostate cancer relies on cancer stem cells.
  • Eliminating prostate cancer stem cells is crucial but lacks established strategies.
  • Natural killer (NK) cells target stem cells in other tumors but not yet prostate cancer.

Purpose of the Study:

  • To investigate the potential of NK cells to selectively target androgen-dependent prostate cancer stem cells.
  • To explore NK cell-mediated elimination strategies for prostate cancer stem cells.

Main Methods:

  • Prostate cancer stem-like cells were isolated from LNCaP cells using 3D culture.
  • Co-culture assays with LNCaP stem-like cells and human NK cells (KHYG-1) were performed.
  • Cell viability (WST-8), protein expression (FACS), and mRNA levels (real-time PCR) were analyzed.

Main Results:

  • NK cells (KHYG-1) exhibited greater cytotoxicity against prostate cancer stem-like cells compared to standard LNCaP cells.
  • The enhanced cytotoxicity was significantly linked to the TRAIL/DR5 cell death pathway.

Conclusions:

  • NK cells demonstrate preferential targeting of prostate cancer stem-like cells.
  • The TRAIL/DR5 pathway is implicated in NK cell-mediated elimination of prostate cancer stem cells.

Related Concept Videos

Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Cells of the Innate Immune Response01:28

Cells of the Innate Immune Response

The innate immune response is an immediate and non-specific response against pathogens, acting swiftly to prevent the spread of infections. The primary cells involved in this response are phagocytes and natural killer (NK) cells.
Phagocytes
Phagocytes police the peripheral tissues by removing cellular debris and responding to the invasion of foreign substances or pathogens. Many phagocytes attack and remove microorganisms even before lymphocytes detect them. The human body has two general...
5.9K
Enzyme-linked Receptors01:00

Enzyme-linked Receptors

Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
80.6K